Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $121,341.27 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Bioventures 2014 L.P. Mpm sold 94,063 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $1.29, for a total transaction of $121,341.27. Following the sale, the insider directly owned 6,147,610 shares of the company’s stock, valued at $7,930,416.90. The trade was a 1.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Friday, October 31st, Bioventures 2014 L.P. Mpm sold 114,044 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.28, for a total transaction of $145,976.32.
• On Thursday, October 30th, Bioventures 2014 L.P. Mpm sold 86,936 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.43, for a total transaction of $124,318.48.
• On Wednesday, October 29th, Bioventures 2014 L.P. Mpm sold 134,240 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.55, for a total transaction of $208,072.00.
• On Tuesday, October 28th, Bioventures 2014 L.P. Mpm sold 69,068 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.64, for a total transaction of $113,271.52.
• On Monday, October 27th, Bioventures 2014 L.P. Mpm sold 72,709 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.72, for a total transaction of $125,059.48.

Werewolf Therapeutics Stock Performance

Shares of HOWL remained flat at $1.31 during midday trading on Monday. 712,892 shares of the stock traded hands, compared to its average volume of 494,803. Werewolf Therapeutics, Inc. has a 52 week low of $0.60 and a 52 week high of $2.52. The company has a market capitalization of $59.91 million, a price-to-earnings ratio of -0.80 and a beta of 0.73. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.30 and a quick ratio of 5.30. The company’s fifty day simple moving average is $1.62 and its 200 day simple moving average is $1.32.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.10. As a group, equities research analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. MPM Asset Management LLC boosted its position in Werewolf Therapeutics by 0.6% during the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock worth $4,189,000 after purchasing an additional 25,688 shares during the period. MPM Bioimpact LLC raised its stake in shares of Werewolf Therapeutics by 0.9% in the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after purchasing an additional 20,799 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after purchasing an additional 25,882 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Werewolf Therapeutics in the second quarter valued at $409,000. Finally, Marshall Wace LLP acquired a new position in shares of Werewolf Therapeutics in the second quarter valued at $113,000. Institutional investors own 64.84% of the company’s stock.

Analyst Upgrades and Downgrades

HOWL has been the topic of several recent analyst reports. Citigroup restated a “buy” rating on shares of Werewolf Therapeutics in a report on Monday, August 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Bank of America cut their price objective on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, August 25th. JMP Securities cut their price objective on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a report on Thursday, August 21st. Finally, Zacks Research upgraded Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Werewolf Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $8.00.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.